Alphatec CEO 'Profoundly Irritated' As Rivals Pick Off Biologics, Dragging Revenue To $221 Million
Pat Miles promises carrot-and-stick fixes after biologics fell about $1 million and the company lowered its 2026 revenue outlook.
Alphatec, which makes spinal implants and surgical technology, lowered its 2026 revenue outlook to about $862 million, and Chairman and CEO Pat Miles said on the company's third-quarter earnings call Thursday that rivals are skimming off its biologics sales because of a lack of sales discipline.
"Profoundly irritated" by biologics leakage
Asked by an analyst at BMO Capital Markets what the company's pledge to "own and address" the problem meant, Miles answered: "Own it means I'm profoundly irritated by it, and it's a lack of discipline that we're going to respond to." He said it feels like "getting pickpocketed a little bit" on the most undifferentiated piece of the procedure.
The response, he said, is carrot and stick across the sales force, accountable sales managers and tighter enforcement of exclusivity terms in distributor agreements. He also said the company is gaining contractual access to more hospitals.
Miles told a Jefferies analyst that procedure volume growth of about 20% puts "a big target on our back" for companies that sell only biologics, which undermines the value of each case.
Quarter and the lowered outlook
Revenue reached $221 million, up 13%, with surgical revenue of $202 million, up 14%. Surgical volumes grew about 20% and new surgeon growth about 25%, but revenue per case fell 5%, mainly on a lower biologics attachment rate.
CFO Todd Koning said biologics revenue fell about $1 million from a year earlier, so hardware drove all of the surgical growth. Biologics have typically added $15 million to $25 million of annual growth, he said, and the new guidance assumes flat biologics from the third to the fourth quarter.
For the year, the company now expects surgical revenue of about $789 million and EOS imaging revenue of about $73 million. Adjusted EBITDA is guided to about $137 million, a 16% margin, and free cash flow to $10 million. Koning cited a temporary international supply constraint worth about $3 million, plus softer thoracolumbar volumes that he tied to the market.
Hospital bidding and the company's own gap
Responding to a Stifel analyst, Miles said hospitals that run a spine bid and a separate biologics bid give smaller companies a "hunting license" to accept lower prices and pay distributors higher commissions. He added that Alphatec is underperforming its accessible market regardless.
Miles said Alphatec expects to be the second company with a BMP, a distinct biologic, around 2029. Koning declined to give 2027 guidance and said he would "err on the side of caution" on biologics until there is more clarity, with the fourth quarter to be watched.
Miles closed the call by calling it a "frustrating quarter" while insisting the company's best days are ahead.
Sources
- Alphatec Non-GAAP EPS of $0.09 in-line, revenue of $221M misses by $4.14M (ATEC:NASDAQ) — seekingalpha.com
- Alphatec: Q3 Earnings Snapshot — Associated Press
- Alphatec: Q3 Earnings Snapshot | king5.com — Associated Press
- Alphatec Holdings Inc. v. NuVasive, Inc. — law360.com
- ATEC Reports Third Quarter Financial Results — businesswire.com